Our differentiated approach combines human genetic data, deep biological and clinical expertise, and rigorous program selection. We focus on targets with well-established human validation and clear mechanistic rationales to develop first- or best-in-class molecules that deliver transformative benefits in the evolving obesity treatment landscape.
Alveus’ lead program ALV-100 – a GIPR antagonist/GLP-1 agonist Fusion Protein – is designed to harness the synergistic effects of these mechanisms to deliver sustainable weight loss resulting in reduced treatment burden for patients.
Importantly, this durable dual approach aims to provide differentiated efficacy beyond current options by addressing counterregulatory metabolic mechanisms and improving long-term outcomes.
Human genetic studies and functional mapping highlight the incretin axis as a key regulator of metabolic health. Loss-of-function variants in GIPR are associated with lower BMI and improved cardiometabolic traits, and GLP-1 receptor agonists are proven to deliver clinically validated benefits in metabolic diseases.
Competitive in vitro potency and weight loss with lean mass preservation in obese NHPs. Weight loss and weight maintenance demonstrated in Ph1.
Central GIP receptor antagonism enhances the weight loss effects of GLP-1R agonism and may allow for infrequent dosing.
Novel recombinant humanized GIPR antagonist IgG-4 antibody – GLP1 agonist peptide fusion protein.